What drove the ADXN.SW stock rise today?

ADXN.SW stock rose **11.43%** on higher-than-average volume (339,147). The move reflects renewed investor interest in Addex’s CNS drug programs and short-term technical oversold bounces rather than confirmed trial data.

What is Meyka AI’s forecast for ADXN.SW stock?

Meyka AI's forecast model projects a **quarterly price of CHF 0.05** for ADXN.SW stock, implying **~28.21%** upside versus the current **CHF 0.039**. Forecasts are model-based projections and not guarantees.

Is ADXN.SW stock a value or speculative play?

ADXN.SW stock is speculative: price-to-book under **1.00** provides some asset cover, but negative EPS, high price-to-sales, and small market cap make it a development-stage biotech play dependent on clinical and licensing catalysts.

How liquid is ADXN.SW stock for traders?

Liquidity is low but today’s relative volume was **1.58** (339,147 vs avg 212,148). Expect wide spreads and rapid moves; use limit orders and smaller positions when trading ADXN.SW stock.

CH Stocks

ADXN.SW Addex Therapeutics (SIX) +11.43% to CHF0.039 23 Mar 2026: catalysts ahead

ByDanny Kontos March 24, 2026

ADXN.SW stock led today’s small-cap gains on the SIX, rising 11.43% to CHF 0.039 on 23 Mar 2026 as volume jumped to 339,147 shares. The move followed renewed investor interest in Addex Therapeutics Ltd’s CNS pipeline and higher-than-average trading versus a 50-day average of 212,148. We review why this intraday gain matters, how liquidity and fundamentals look in Switzerland, and what the Meyka AI grade and forecasts imply for short- and medium-term traders.